
    
      The primary objective of this study is to evaluate the efficacy and safety of buprenorphine
      transdermal system (BTDS) compared to placebo in subjects with moderate to severe low back
      pain who have a sub-optimal response to their non-opioid analgesic treatment and require
      opioid analgesics for pain control.
    
  